Federal contractor · SAN DIEGO, CA

NOVOMEDIX LLC

No contract obligations recorded for NOVOMEDIX LLC in FY2026. Since FY2022: $3.3M. Its largest customer was National Institutes of Health ($0). It also received $356K in federal grants and other assistance in FY2026.

Obligations · FY2026
$0
New awards
1
Sole-source
—
Single offer
—
UEI
XQYMHKGDMU75
Small businessWoman-owned
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 355KFY2022
  2. 0FY2023
  3. 0FY2024
  4. 3MFY2025
  5. 0FY2026

Top buying agencies

Obligations in FY2026.

  1. National Institutes of Health$00.0%
    1 awards

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Largest awards

  1. SBIR PHASE II - ENHANCED OVERALL SURVIVAL IN HIGH-RISK PEDIATRIC SOLID TUMORS USING A NOVEL ORAL SMALL MOLECULE$3M
    National Institutes of Health· San Diego County, CA· Research & development· Sep 15, 2025 – Sep 24, 2026· 75N91025C00051

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

NOVOMEDIX LLC received $356K in federal assistance in FY2026, on 3 actions (1 new awards), +13% vs FY2025. Its largest program was 93.837 · Cardiovascular Diseases Research ($356K).

Assistance · FY2026
$356K
New awards
1
Actions
3
Since FY2021
$3.8M

Assistance by fiscal year

  1. 375KFY2021
  2. 1.1MFY2022
  3. 930.6KFY2023
  4. 806.9KFY2024
  5. 314.4KFY2025
  6. 356KFY2026

By type

  1. Grants$356K100%

Top programs

  1. 93.837 · Cardiovascular Diseases Research$356K100%

Awarding agencies

  1. National Institutes of Health$356K100%
    Department of Health and Human Services

Largest awards

  1. NOVEL SMALL MOLECULE FOR THE PREVENTION AND TREATMENT OF DMD CARDIOMYOPATHY - PROJECT SUMMARY DUCHENNE MUSCULAR DYSTROPHY (DMD) IS THE MOST…$356K
    93.837 · Cardiovascular Diseases Research· National Institutes of Health· Project grant· Aug 24, 2026 – Aug 24, 2026· R43HL182659
  2. ARTHROFIBROSIS CONTROL USING SMALL MOLECULE INHIBITORS OF INTERLEUKIN-11 - ABSTRACT THIS PROGRAM AIMS TO DEVELOP AND COMMERCIALIZE A NOVEL…$314.4K
    93.846 · Arthritis, Musculoskeletal and Skin Diseases Research· National Institutes of Health· Project grant· Sep 22, 2025 – Jun 30, 2026· R43AR086064
  3. NOVEL ORAL SMALL MOLECULES FOR PROGRESSIVE PULMONARY FIBROSIS - ABSTRACT THE OVERALL GOAL OF THIS PROGRAM IS THE DEVELOPMENT AND…$306.9K
    93.837 · Cardiovascular Diseases Research· National Institutes of Health· Project grant· Sep 18, 2024 – Jul 8, 2026· R43HL176343

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 8, 2026, loaded Oct 8, 2026 · FY2021–FY2026.

Competitors

Companies that win from the same buyers in the same markets: obligations by agency and industry compared over the last three fiscal years.

Compared on 1 market (agency × industry), FY2024–FY2026.

  1. CONTINUITY BIOSCIENCES, LLC$3M−100% in FY2026
    BRADENTON, FL · 100% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services
  2. DESIGN-ZYME LLC$3M
    LAWRENCE, KS · 100% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services
  3. ADJUVAX LLC$3M−100% in FY2026
    HOOVER, AL · 100% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services

Showing the top 3 of 25 competitors. Open the profile for the full list.

Who sells to the same buyers in the same markets, not who wins against whom on a given contract. Prime contract obligations by the agency and NAICS code of each award; subawards are never added. A company is a family of legal entities, joined by parent UEI or, in part, by an AI reading of names.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 9, 2026, loaded Oct 9, 2026 · FY2024–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 9, 2026, loaded Oct 9, 2026.